Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis ...Middle East

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an...

Hence then, the article about immunic inc announces positive top line data from investigator sponsored phase 2 proof of concept clinical trial of imu 838 in primary sclerosing cholangitis was published today ( Thursday 18/02/2021 - 03:01 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis )

Also on site :

• Widow who lost life savings in romances scams died in Ghana crash after traveling ‘for marriage’
• New York lawsuits target prediction market giants Coinbase and Gemini in major showdown
• Former Nigerian general among six charged with treason